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terial agents.4-7 Rifampicin has a broad-spectrum antibac-
terial activity against most aerobicgram-positive and gram-
negative organisms, including methicillin-resistant
Staphylococcus aureus (MRSA) or Escherichia coli,8 and has
a favorable chemical property that easily links to gelatin in
a form of ionic bonding by merely soaking in a rifampicin
solution.9-11 Therefore, in current reports regarding infec-
tion-resistant grafts, the rifampicin-gelatin grafts have
been exclusively tested in an experimental study9,10,12-14
and favorable clinical results have also been reported.15-17
Nevertheless, sufficient efficacy and duration of infection
resistance to commonly causative organisms are the most
important concerns for further clinical prevalence of
rifampicin-gelatin grafts.6,13,18,19 A possibility of applica-
tion to established graft infections as the result of virulent
organisms is an important problem to be clarified. E coli
graft infection after primary bypass surgery occupies 12%
to 30% of the causative organisms in aortoiliac or femoral
Vascular graft infection has a significant incidence rate
of 0.77% to 3.0% in aortofemoral bypasses1,2 or a 3% rate
in thoracic aorta replacement,3 which results in higher limb
loss or mortality rates. To provide effective prophylaxis or
management of established graft infection, many attempts
have been made to impregnate grafts with various antibac-
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Objective: Efficacy and duration of antibacterial activity of rifampicin-gelatin grafts against virulent organisms were
evaluated in an animal model.
Materials and methods: Rifampicin-gelatin grafts were prepared with impregnation of Gelseal (Vascutek Ltd, Scotland)
graft in 1 mg/mL rifampicin solution. Rifampicin-gelatin grafts (6 cm long; n = 24) and plain Gelseal grafts as con-
trols (n = 4) were implanted into the canine abdominal aorta with inoculation of Staphylococcus epidermidis, Escherichia
coli, or methicillin-resistant Staphylococcus aureus (MRSA), and the rifampicin-gelatin grafts were retrieved after 1 to 4
weeks. Disks cut from the retrieved rifampicin-gelatin grafts were placed on agar plates streaked with one of the organ-
isms, and the graft antibacterial activity was assessed with the width of the inhibition zone.
Results: In in vitro tests, initial inhibition zones (inhibition zone of 24 hours after incubation) of rifampicin-gelatin
grafts against S epidermidis, MRSA, and E coli were 40.0 ± 0.3 mm, 36.0 ± 0.2 mm, and 11.8 ± 0.1 mm, respectively.
In the implantation, S epidermidis–inoculated rifampicin-gelatin grafts had no findings of graft infection, and no colony
growth was recognized on the plates streaked with the perigraft fluids. Initial inhibition zones of S epidermidis–
inoculated rifampicin-gelatin grafts retrieved at 1 or 2 weeks were 20.1 ± 1.1 mm and 7.6 ± 1.0 mm, respectively. In
E coli–inoculated and MRSA-inoculated rifampicin-gelatin grafts, all of the eight animals had perigraft abscess, and
blood culture test results probed septicemia in five animals with patent grafts at death. Inhibition zones against E coli
or MRSA were not formed on the plates streaked with the same organism, whereas initial inhibition zones of E
coli–inoculated and MRSA-inoculated rifampicin-gelatin grafts on S epidermidis-streaked plates were 8.0 ± 0.2 mm and
18.5 ± 0.5 mm, respectively. In the MRSA group, however, recolonization of high minimal inhibitary concentration
strains developed within the inhibition zones as early as 24 hours. Histologically, neither organisms nor inflammatory
cells were found in S epidermidis–inoculated rifampicin-gelatin grafts and tissue ingrowth was recognized at 2 to 4
weeks, whereas E coli–inoculated and MRSA-inoculated rifampicin-gelatin grafts had aggressive neutrophil infiltration
into the graft interstices, revealing establishment of uncontrollable graft infection.
Conclusion: These results suggested that rifampicin-gelatin grafts are clearly valid for S epidermidis infection, whereas
no efficacy was recognized against either MRSA or E coli graft infection because of early development of high minimal
inhibitary concentration MRSA strains or poor susceptibility. (J Vasc Surg 2002;35:779-85.)
graft infection,2 and the incidence rate of MRSA graft
infection is high. Several investigators20,21 have suggested
that in situ replacement with rifampicin-gelatin grafts
against MRSA infection is probably unwise. However,
data regarding efficacy of rifampicin-gelatin grafts against
these virulent organisms are limited. In this study, efficacy
and duration of antibacterial activity of rifampicin-gelatin
grafts against virulent organisms were examined with in
vitro testing and an animal model, and the possibility of
clinical application of rifampicin-gelatin grafts for manage-
ment of established graft infection, and as prophylaxis
against graft infection, was explored through use of a
high-level inoculation model. 
MATERIALS AND METHODS
Preparation of rifampicin solution and rifampicin-
gelatin grafts. Because rifampicin with solvent is not
available in Japan, our rifampicin solution was prepared
from oral type rifampicin powder (Daiichi Pharmaceutical
Ltd, Tokyo, Japan). The rifampicin solution processed in
our laboratory gradually decreases antibacterial activity at
room temperature because of oxidation. Therefore, the
solution was prepared 24 hours before use and kept in a
refrigerator. The preparation procedure was as follows:
100 mg of rifampicin powder was dissolved in 95 mL of
0.05 mol phosphate buffer saline solution (pH, 8.0), 100
mg of ascorbic acid and 490 mg of NaCl were added, and
0.1% rifampicin solution (1 mg/mL, with 270 mOsm;
pH, 7.40) was then obtained and sterilized with filtra-
tion through a 0.22-m–cellomembrane filter. Before in
vitro or implantation tests, a gelatin-sealed polyester
graft (Gelseal graft; Vascutek Ltd, Scotland) was soaked
in the rifampicin solution for 30 minutes at room temper-
ature and excess solution was wiped off immediately
before implantation. The plain Gelseal graft was implanted
as a control.
Preparation of Bacteria
Bacteria used in this study were coagulase negative
Staphylococcus (Staphylococcus epidermidis), MRSA, and 
E coli (American Type Culture Collection No. 25922).
These rapid growing–type strains were common
pathogens of postoperative graft infection, and the former
two were obtained as clinical isolates from the clinical
examination laboratory in the Asahikawa Medical
University Hospital. A small aliquot of each isolate was
streaked onto each appropriate culture plate and incu-
bated at 35°C. After 24 hours, the colonized plate was
then stored at 5°C in a refrigerator for later use. E coli was
incubated and stored on a Trypt-soy agar plate, and the
other two were stored on blood agar plates. Twenty-four
hours before, an aliquot obtained from colonies on the
stored plate was streaked on each specific agar plate, and
the plate was incubated at room temperature to obtain
sufficient colonies. In the implantation study, with the
increased colonies of each organism strain, organism solu-
tions were prepared. Briefly, some of the colonies were
diluted with a physiologic saline solution (NaCl, 0.85%
Medium; biomerieux sa, Marcy L’Etoile, France), and the
desired concentration in compliance with the recommen-
dation of the National Committee for Clinical Laboratory
Standards (NCCLS)22 was automatically produced with a
colorimeter (ATB 1500, Vitek Systems Co, Japan). In this
study, 1  108/mL of organism concentration was used
for graft inoculation. 
Antibacterial susceptibility test of rifampicin-gelatin
grafts. To assess antibacterial activity of rifampicin-gelatin
grafts, four round disks with a diameter of 6 mm were cut
from each graft segment and placed on a Müller-Hinton
agar plate, which had been inoculated with one of the pre-
ceding bacteria, and incubated at 35°C for 24 hours.
Diameters of the inhibition zones formed surrounding the
four disks were measured, and the antibacterial activity of
the grafts was expressed with the mean diameter of the
four inhibition zones. In this study, susceptibility criteria
were on the basis of the NCCLS.22 According to the cri-
teria, clinical efficacy is divided into three levels: suscepti-
ble, intermediate, and resistant. The relations between
each level and minimum inhibitary concentration (MIC)
in rifampin are as follows: in S aureus, susceptible more
than 35 mm, intermediate 26 to 34 mm, and resistant less
than 25 mm; and in E coli, susceptible more than 11 mm,
intermediate 8 to 10 mm, and resistant less than 7 mm.
MICs were 0.01 to 0.5 g/mL for Staphylococci, includ-
ing MRSA, and less than 12 g/mL for E coli.8 In our
preparation method, concentration of rifampicin was most
stable at 1 mg/mL, and susceptibilities of MRSA and E
coli to rifampicin were considered to be at significant lev-
els when the inhibition zones were more than 35 mm and
more than 11 mm or more, respectively. Because the max-
imal inhibition zone was established within 24 hours after
incubation, the mean diameter at 24 hours was defined as
the initial inhibition zone, which was compared among
the three bacteria strains. 
JOURNAL OF VASCULAR SURGERY
780 Koshiko et al April 2002
Fig 1. In vitro antibacterial susceptibility test results of
rifampicin-gelatin grafts. Recolonization (arrows) of resistant
strain of MRSA developed within inhibition zone as early as 3
days after incubation.
Evaluation of rifampicin-gelatin graft infection 
resistance in an animal model. Twenty-eight randomly
selected mongrel dogs of both sexes, weighing 10 to 15
kg (average, 14.4 ± 0.58 kg), were used for implantation.
The study was approved by the Institutional Review
Board, and animal care complied with the “Guide for the
Care and Use of Laboratory Animals,” Institute of
Laboratory Animal Resources, Commission on Life
Sciences, National Research Council (Washington:
National Academy Press, 1996). All the animals were
anesthetized with intravenous thiamylal sodium, intu-
bated, and ventilated with 33% oxygen, and a median
laparotomy was performed with aseptic conditions. After
intravenous administration of heparin, rifampicin-gelatin
grafts (6 cm long; n = 24) and plain Gelseal grafts as con-
trols (diameter, 6 mm; n = 4) were implanted into the
canine infrarenal abdominal aorta in end-to-end anasto-
moses with 5-0 polypropylene continuous sutures.
Immediately after aortic declamping, the graft was
infected with direct inoculation with 2 mL of one of the
three organism solutions with a concentration of 1 
108/mL, and the retroperitoneum and laparotomy then
were closed in layers. No antibiotics were given during the
experimental period. The implantation study was per-
formed in compliance with the vertebrate animal
biosafety-level criteria in microbiologic and biomedical
laboratories.23 The infected animals were housed in pri-
mary biosafety containment equipment, and their care
complied with the guidelines of animal biosafety level 2.
Graft retrieval and examination. Of 28 animals, 20 were
used for S epidermidis innoculation study. Of those 20, 16
were used for implantation of S epidermidis–inoculated
rifampicin-gelatin grafts, which were retrieved at 1, 2, 3,
or 4 weeks after implantation, and their healing process
after organism innoculation was examined. Four were
used for implantation of plain Gelseal grafts as controls,
which were removed at 1 week. The remaining eight ani-
mals were used for MRSA or E coli innoculation study;
four each were used for implantation of rifampicin-gelatin
grafts inoculated with MRSA or E coli, which were
retrieved at, or within, 1 week. At the removal, all of the
animals were anesthetized, and arterial blood sampling
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was performed for examination of septicemia. The graft
was reexplored aseptically, direct graft imprinting on each
specific agar plate was used for bacterial recovery, and peri-
graft fluid and tissue swabs were also streaked and cul-
tured. After intravenous administration of heparin, the
animals were killed with an overdose of potassium chlo-
ride. The graft, including both anastomoses, was carefully
removed and longitudinally opened for inspection of the
luminal surface, and four disks were obtained from each
organism-innoculated graft. At first, to examine the resid-
ual antibacterial activity of the rifampicin-gelatin grafts,
the four disks were placed on a Müller-Hinton agar plate
inoculated with the same bacteria and incubated at 35°C.
The E coli–inoculated rifampicin-gelatin graft disks and
the MRSA-inoculated rifampicin-gelatin graft disks also
were tested on the S epidermidis–streaked plates. The
residual portions of each graft after disk removal were
rinsed once with a saline solution, and direct graft imprint-
ing on the agar plates was performed for bacterial recov-
ery. The agar plates were incubated overnight. When the
specific colony growth was recognized, it was considered
that the graft had been infected. After the direct graft
imprinting, the residual portions of each graft were fixed
with 10% buffered formalin for 24 hours, cross-sectioned,
embedded in paraffin, and stained with hematoxylin and
eosin and Elastica van Gieson. 
RESULTS
In vitro susceptibility test of organisms to rifampicin-
gelatin graft
For in vitro test results of rifampicin-gelatin grafts, the
mean diameters of initial inhibition zones against S epi-
dermidis, MRSA, and E coli were 40.0 ± 0.3 mm, 36.0 ±
0.2 mm, and 11.8 ± 0.1 mm, respectively (Table I). These
results suggested that rifampicin-gelatin grafts used in this
study were valid and useful for S epidermidis, whereas the
efficacy against E coli was insufficient but susceptible. In
the MRSA group, despite the sufficient values of initial
inhibition zone, recolonization of MRSA strains with high
level MICs developed within the inhibition zone as early
as 3 days after incubation (Fig 1), which suggests that
MRSA had no bacterial antibiotic susceptibility to
rifampicin-gelatin grafts as well. 
Table I. In vitro susceptibility testing of organisms to rifampicin-gelatin grafts
Diameters of inhibition zone (mm)
Time after incubation S epidermidis MRSA E coli
24 hours (IIZs) 40.0 ± 0.3 36.0 ± 0.2 11.8 ± 0.1
2 days 36.5 ± 0.4 32.5 ± 0.2 9.0 ± 0.2
5 days 34.6 ± 0.4 30.4 ± 1.2 0
1 week 30.6 ± 0.4 24.2 ± 0.8 –
2 weeks 26.3 ± 0.5 15.6 ± 1.6 –
3 weeks 18.2 ± 1.0 0 –
Values are mean ± standard deviation of four discs. 
IIZs, Initial inhibition zone.
Implantation study
Staphylococcus epidermidis. All of the 20 grafts
were patent at the time of removal, and no perigraft
abscess was recognized in either the rifampicin-gelatin
graft or control groups. However, in bacteriologic culture
of the graft, perigraft fluid, and tissue swabs, no growth of
an S epidermidis strain was recognized in the rifampicin-
gelatin graft group, whereas many colonies were formed
within 24 hours after incubation in the control group,
which suggests graft infection. Mean initial inhibition
zones of S epidermidis–inoculated rifampicin-gelatin graft
disks retrieved at 1 and 2 weeks were 20.1 ± 1.1 mm and
7.6 ± 1.0 mm, respectively (Table II), which shows a sig-
nificant duration of the antibacterial activity. These inhibi-
tion zones disappeared at 3 weeks, and no inhibition zones
were formed in controls.
Histologically, control grafts inoculated with S epider-
midis showed severe neutrophil infiltration in the outer tis-
sue capsule and into the graft interstices through defects of
the sealant at day 7, whereas neither organisms nor inflam-
matory cells were found in S epidermidis–inoculated
rifampicin-gelatin grafts retrieved at 1 to 4 weeks (Fig 2,
A). Sufficient gelatin sealants of S epidermidis–inoculated
rifampicin-gelatin grafts remained after 2 weeks, but most
of them had been absorbed at 3 weeks. Fibrous tissue
ingrowth was recognized in S epidermidis–inoculated
rifampicin-gelatin grafts retrieved at 2 to 4 weeks (Fig 2,
B), proving that S epidermidis infection had been thor-
oughly prevented.
MRSA. Of four animals, one died within 7 days.
Perigraft abscess was recognized in all of the four
rifampicin-gelatin grafts. Three animals with patent grafts
were in distress at death, and blood bacteriologic culture
tests probed MRSA septicemia. In the bacteriologic cul-
ture test for the retrieved rifampicin-gelatin grafts, no
colonies developed on the plates that were directly
streaked with the retrieved MRSA-inoculated rifampicin-
gelatin grafts, whereas many colonies were formed within
24 hours in the plates streaked with the perigraft fluid or
tissue fragments. Aggressive MRSA recolonization with-
out initial inhibition zones around MRSA-inoculated
rifampicin-gelatin graft disks formed on MRSA-streaked
plates. Although significant initial inhibition zones with
mean diameters of 18.5 ± 0.5 mm had formed on the S
epidermidis–streaked plates (Table II), recolonization of
MRSA strains with high level MICs developed within the
inhibition zone as early as 24 hours, which was earlier than
that observed in rifampicin-gelatin grafts in the preimplan-
tation test. Histologically, MRSA-inoculated rifampicin-
gelatin grafts had marked perigraft abscess with aggressive
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Fig 2. Photomicrographs of rifampicin-gelatin grafts after implantation. S epidermidis–inoculated rifampicin-gelatin grafts at day 7 show
no inflammatory responses (A) and at day 14 show good healing (B). MRSA-inoculated and E coli–inoculated rifampicin-gelatin grafts
show aggressive neutrophil infiltration in outer capsule (C, MRSA) and graft interstices (D, E coli). Cross-section, hematoxylin and eosin.
L, Luminal surface.
A
B
C
D
neutrophil infiltration (Fig 2, C), revealing establishment
of graft infection. 
E coli. Of four animals, two died within 7 days.
Perigraft abscess was recognized in all of the four
rifampicin-gelatin grafts, and blood bacteriologic culture
tests probed E coli septicemia in two animals with patent
grafts at death. In the bacteriologic culture test, no
colonies developed in direct imprinting with the retrieved
E coli–inoculated rifampicin-gelatin grafts, whereas many
colonies were formed within 24 hours in the plates
streaked with the perigraft fluid or tissue fragments. As
with MRSA, aggressive high MIC E coli recolonization
around E coli–inoculated rifampicin-gelatin graft disks
formed on the plates streaked with E coli, without initial
inhibition zone formation. However, significantly sized
initial inhibition zones with a mean diameter of 8.0 ± 0.2
mm were formed on S epidermidis–streaked plates (Table
II). These results revealed that, although the susceptibility
of E coli to rifampicin-gelatin grafts was poor, rifampicin-
gelatin grafts still retained their antibacterial activity for as
long as they did against S epidermidis.
Histologically, E coli–inoculated rifampicin-gelatin grafts
had marked perigraft abscess with aggressive neutrophil infil-
tration as well. As seen in S epidermidis–inoculated and
MRSA-inoculated rifampicin-gelatin grafts, sufficient gelatin
sealant of E coli–inoculated rifampicin-gelatin grafts still
remained 1 week after implantation, but there was neu-
trophil infiltration into the graft interstices through the
sealant defects (Fig 2, D), revealing establishment of graft
infection. 
DISCUSSION
Use of antibacterial vascular grafts has two objectives:
prophylactic use in primary vascular reconstruction and
management of mycotic aneurysms or established graft
infections. In the former, unusual postoperative healing
processes, such as perigraft hematoma, prolonged lym-
phatic discharge, or accumulation, are relevant inducing
factors of graft infection. In the latter, replacement of
infected grafts with extraanatomic bypasses has been pref-
erentially used, and Yeager et al24 reported satisfactory
results for infrarenal aortic infection. Nevertheless, in situ
replacement has definite surgical and anatomic advantages
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when compared with the extraanatomic technique, which
is a longer procedure with substantial risks of morbidity
and mortality. In addition, the use of autogenous material
for replacement is often not practical. Hence, cryopre-
served arterial homografts have been used for in situ
replacement25,26 and rifampicin-gelatin grafts7,10-17 have
been studied as an alternative material because of the
potential advantages of easier procurement and handling,
when compared with cryopreserved arterial homografts.
The definitive efficacy of rifampicin-gelatin grafts still
remains unclear. The rifampicin retention in the graft
results from the ionic bond formation between the nega-
tively charged free carboxyl groups of the gelatin and the
positively charged radicals of rifampicin.10,16 The esti-
mated elution half lives of protein-sealed grafts were
reported to be 4 to 141 hours.11 However, the rifampicin
retention after implantation is restricted, not only by
absorption of the antibiotic itself, but also by degradation
of the gelatin sealant. Although Drury et al27 reported
that the gelatin sealant of Gelseal grafts was mostly
absorbed within 7 to 10 days after implantation, this study
confirmed that a significant amount of gelatin was
retained on the graft surface for 2 weeks after implantation
and sufficient antibacterial activity of the retrieved
rifampicin-gelatin grafts was retained up to 2 weeks after
implantation. Therefore, it was suggested that effective
infection resistance is maintained for 2 weeks and that the
loss of antibacterial activity is the result of the resorption
of the gelatin sealant rather than of release or inactivation
of rifampicin itself.
Rifampicin is not only the most effective antibiotic for
mycobacterium tuberculosis but also has a wide antibacte-
rial activity against both gram-positive and gram-negative
bacterial strains. The mechanism of the action is RNA dis-
ruption with DNA-dependent RNA polymerase.28
However, the identity of organism strains susceptible to
rifampicin-gelatin graft still remains unclear. In this study,
we tested S epidermidis as the most frequent pathogen of
biofilm infection18,19 and E coli as the most virulent gram-
negative bacterium. In addition, the currently highlighted
organism, MRSA, was also tested because there was no
definitive study regarding the efficacy of rifampicin-gelatin
graft on MRSA, regardless of the poor outcome of MRSA
Table II. Infection resistance of organism-inoculated rifampicin-gelatin grafts on Staphylococcus epidermidis–streaked
plates
Diameters of initial inhibition zone (mm)
Implantation periods S epidermidis MRSA E coli
1 week 20.1 ± 1.1 18.5 ± 0.5 8.0 ± 0.2
(n = 4) (n = 4) (n = 4)
2 weeks 7.6 ± 1.0 – –
(n = 4)
3 weeks 0 – –
(n = 4)
Number of rifampicin-gelatin grafts (n = 4).
graft infection.20 For in vivo assessment of the efficacy of
rifampicin-gelatin grafts, bacteria-challenging animal mod-
els have been used in the previous studies, where various
organism concentrations for inoculation were adopted,
with a range of 102 to 1.0  108 mL.4,6,7 According to the
guidelines of the NCCLS for antibiotic susceptibility test-
ing,29 use of Macfarand 0.5 solution, which is 1 to 2  108
colony forming units (CFU)/mL, is recommended. We
used a direct culture method instead of a bacterial culture
method with a broth, and in our preliminary study, bacte-
rial concentration of 1  108 CFU/mL was obtained at
McFarland 1.0. We presumed that the difference in con-
centration probably was the result of the use of the direct
culture technique. Neverthless, 108 is still a high level, but
the NCCLS recommended this concentration for antibac-
terial activity testing. In this study, the grafts were infected
with inoculation with 2 mL of the organism solution with
108 CFU/mL, which is the concentration when graft
infection was established and the organism number had
reached a plateau.28 This organism concentration was the
highest when compared with those in the previous studies.
However, in clinical use, it would be essential to confirm a
significant efficacy of rifampicin-gelatin grafts as shown in
the test results of S epidermidis in this study.
Rifampicin solution has two disadvantages as an
antibacterial agent: the first is loss of antibacterial activity
because of oxidation in room temperature. Sano and
Tunakawa9 reported that inactivation was greatly sup-
pressed at neutrality or in lower temperatures. In this
study, the loss of antibacterial activity was solved with
preparation 1 day before use and storage in a refrigerator.
Rifampicin-gelatin grafts were sufficiently effective against
S epidermidis infection both in in vitro tests and animal
implantation. However, E coli was not susceptible to the
rifampicin-gelatin grafts retrieved 1 week after implanta-
tion, and no organisms were recovered from MRSA-inoc-
ulated and E coli–inoculated rifampicin-gelatin grafts in
the direct imprinting technique. As shown in Table II, the
organism-inoculated rifampicin-gelatin grafts still con-
tained rifampicin at 1 week after implantation. Therefore,
we speculated that the rifampin bonding the grafts inhib-
ited the growth of E coli only on the graft surface but was
in insufficient concentration to affect the surrounding tis-
sues. There is the other possibility that E coli graft infec-
tion was the result of the relatively low concentration of
rifampicin solution. MICs are 0.01 to 0.5 g/mL for
Staphylococci, including MRSA, and less than 12 g/mL
for E coli.8 In our preparation method, concentration of
rifampicin was most stable at 1 mg/mL, which is about
2000 to 83 times higher than the MICs. Because initial
inhibition zones were more than 35 mm for MRSA and
11 mm or more for E coli, the susceptibilities to rifampicin
of the rifampicin-gelatin grafts were considered to be sig-
nificant levels, in accordance with the guidelines of the
NCCLS.29 In this study, these were 36.0 ± 0.2 mm and
11.8 ± 0.1 mm, respectively, revealing the concentration
of the rifampicin solution to be sufficient. Hence, we con-
sider that 1 mg/mL of rifampicin is sufficient in local
application and the use of high concentration rifampicin
may develop high MIC strains.
The other disadvantage of rifampicin-gelatin grafts is
the well-known tendency to yield high MIC strains,20,30
especially against MRSA, and topical use accelerates this
tendency. Hayes et al20 reported that in situ replacement
with a rifampicin-gelatin graft is probably ineffective for
established graft infection caused by MRSA. In this study,
MRSA was initially sensitive to rifampicin, but high level
MIC strains developed early, and MRSA-inoculated
rifampicin-gelatin grafts formed severe perigraft abscesses,
resulting in serious outcome. Although this implantation
model did not investigate the effect of rifampicin-gelatin
grafts on established graft infection, the results clearly
showed that rifampicin-gelatin grafts are absolutely inap-
plicable against MRSA infection. In a further study, evalu-
ation of the other alternative antibacterial agents, such as
vancomycin or teicoplanin, will be necessary.
In conclusion, the in vitro susceptibility test and
implantation study showed that rifampicin-gelatin grafts
retained sufficient antibacterial activity for 2 weeks and may
be useful both for prophylaxis and established graft infec-
tion against S epidermidis. However, E coli and MRSA
showed no significant susceptibility to rifampicin-gelatin
grafts. Thus, rifampicin-gelatin grafts are not applicable to
management of infections associated with vascular surgery
that are caused by these virulent organisms. 
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